Figure 2From: Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate Changes in the QTc interval in the study subjects following the first infusion of combretastatin A-4 phosphate. Back to article page